Reduced adiponectin levels in patients with COVID-19 acute respiratory failure: A case-control study.
Reduced adiponectin levels in patients with COVID-19 acute respiratory failure: A case-control study.
复制标题
DOI：
10.14814/phy2.14843
复制
发表时间：
2021-04
影响因子：
2.5
通讯作者：
Kadl A
中科院分区：
文献类型：
--
作者：
Kearns SM;Ahern KW;Patrie JT;Horton WB;Harris TE;Kadl A
据推测，低脂联素血症在肥胖与COVID-19呼吸衰竭之间的关系中发挥关键作用。然而，只有一项研究检测了COVID-19患者的脂联素水平，没有一项研究严格研究了急性呼吸衰竭患者的脂联素水平。在这项研究中，我们对COVID-19或其他病毒/细菌来源引起的急性呼吸衰竭患者的脂肪因子水平进行了回顾性病例对照研究。纳入了弗吉尼亚大学生物储存和组织研究数据库中的所有COVID-19呼吸衰竭患者。我们还从同一生物库中选择了非COVID-19感染性呼吸衰竭患者作为比较队列。在住院的前72小时内，测量了三次血浆脂肪因子水平。研究了12例COVID-19呼吸衰竭患者和17例其他感染性呼吸衰竭患者。COVID-19呼吸衰竭患者的脂联素水平显著较低，即使调整了年龄、性别、BMI和其他协变量。总之，脂联素水平似乎在COVID-19呼吸衰竭中降低。需要更大规模的研究来证实这一报告。
Hypoadiponectinemia is speculated to play a key role in the relationship between obesity and COVID‐19 respiratory failure. However, only one study has examined adiponectin levels in COVID‐19 patients, and none have investigated adiponectin levels strictly in patients with acute respiratory failure. In this study, we performed a retrospective case‐control study of adipokine levels in patients with acute respiratory failure caused by either COVID‐19 or other viral/bacterial source. All patients with COVID‐19 respiratory failure in the University of Virginia Biorepository and Tissue Research database were included. We also selected patients with non‐COVID‐19 infectious respiratory failure from the same biorepository to serve as a comparison cohort. Plasma adipokine levels were measured on three occasions during the first 72 hours of hospitalization. Twelve patients with COVID‐19 respiratory failure and 17 patients with other infectious respiratory failure were studied. Adiponectin levels were significantly lower in patients with COVID‐19 respiratory failure, even after adjustment for age, sex, BMI, and other covariates. In conclusion, adiponectin levels appear to be reduced in COVID‐19 respiratory failure. Larger studies are needed to confirm this report.